Sign inJoin waitlistJoin the waitlist

Gregory Kalemkerian

Associate Division Chief for Faculty Development & Education · University of Michigan Medical School

Credentials: · · · ·

History

University of Michigan Medical School
Present
University of Michigan Medical School
Present

Medical Oncology
1988–1990
Internal Medicine
1985–1988
Feinberg School of Medicine
1981–1985

Research

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Journal of Clinical Oncology · 2020 · 649 citations
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement…
Journal of Clinical Oncology · 2018 · First of 14 authors · 401 citations
High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose…
International journal of radiation oncology · 2005 · 393 citations

James Hayman
22 papers
Shirish Gadgeel
21 papers · 3 as a resident
Bryan Schneider
19 papers
Nithya Ramnath
17 papers
AW
Antoinette Wozniak
14 papers
TL
Theodore Lawrence
14 papers
AQ
Angel Qin
12 papers · 2 as a fellow
MK
Michael Kraut
12 papers
DA
Douglas Arenberg
9 papers
Khaled Hassan
9 papers · 2 as a fellow
SJ
Shruti Jolly
8 papers
DB
Dean Brenner
6 papers

Grants

University of Michigan Rogel Cancer Center Support Grant 2023-2028
National Cancer Institute · P30
Project lead · $1.1M · University of Michigan at Ann Arbor
1997–2023

Clinical trials

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
University of Michigan Rogel Cancer Center
2018–2021
Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents
Principal investigator · Completed · Phase 2
University of Michigan Rogel Cancer Center
2017–2025
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Principal investigator · Withdrawn · Early phase 1
University of Michigan Rogel Cancer Center
2015
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
Principal investigator · Completed · Phase 2
University of Michigan Rogel Cancer Center
2007–2011